UA POD to decommissioned at the end of June insidetucsonbusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidetucsonbusiness.com Daily Mail and Mail on Sunday newspapers.
The University of Arizona plans to decommission its vaccination site as of June 25 and announced new hours last Thursday.
With the decline in vaccine demand and âas other avenues for vaccination become more readily available,â the UA POD plans to scale back its hours and on Monday transitioned to fully indoors at the Ina E. Gittings Building, closing the drive-thru as the days get hotter, announced UA President Robert C. Robbins at the university update on Monday morning.
At the start of next week the UA POD will shorten its hours to 10 a.m. to 5 p.m., then on June 1 will continue with new hours only offering second doses.
UA POD To Decommissioned at the End of June tucsonweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tucsonweekly.com Daily Mail and Mail on Sunday newspapers.
The Arizona Department of Health Services yesterday recommended resuming the use of the Johnson & Johnson vaccine after the CDC and FDA safety review Sunday.
On Friday, the Advisory Committee on Immunization Practices voted to recommend the J&J vaccine, but members wanted clear messaging about the possible risks for women younger than 50 years old.
On April 13, the CDC and FDA recommended pausing the vaccine after six reported cases of a rare adverse event among women developed blood clotting with low blood platelets after receiving J&J. The CDC determined the event is rare, occurring at a rate of 7 per 1 million vaccinated women between the age of 18 to 49.
Advertisement: The county is sharing the FDA Fact Sheet, with updated information addressing the concerns that led to the pause. The county has about 12,600 J&J vaccine doses as of Monday. Dr. Richard Carmona, the former U.S. surgeon general and UA Task Force director, said it remains unclear whether the blood clotting is directly related to the vaccine “but the benefit of this vaccine is enough that we all agreed that it should go back to market.” “We need to get this vaccine back out there because it is a very effective vaccine,” said Carmona. However, vaccine demand has stalled nationwide and in the state with tens of thousands of appointments available at state vaccination sites last week.